

CLAIMS

1. A compound characterized in that it is chosen from the compounds capable of binding to hormone receptors and in that it comprises a nitrogen monoxide-donor nitric ester group, with the exception of estradiol substituted in the 11- and/or 17-position with a nitric ester group.
5. 2. A compound as claimed in claim 1, characterized in that the hormone receptors are chosen from steroid receptors, retinoid receptors and vitamin D derivative receptors.
10. 3. A compound as claimed in either one of claims 1 and 2, characterized in that the compound capable of binding to hormone receptors is a natural hormone.
15. 4. A compound as claimed in either one of claims 1 and 2, characterized in that the compound capable of binding to hormone receptors is a synthetic hormone.
20. 5. A compound as claimed in any one of claims 1 to 4, characterized in that the compound capable of binding to hormone receptors is chosen from the group composed of a progestogen hormone, an estrogen, an anti-mineralocorticoid, an androgen or an anti-androgen or a combination of these hormones.
25. 6. A compound as claimed in any one of claims 1 to 5, characterized in that the hormone capable of binding to hormone receptors is chosen from the following group: progesterone, 170H-progesterone, estradiol, ethinyl estradiol, aldosterone, spironolactone, drospirenone, testosterone and cyproterone.
30. 7. A compound as claimed in claims 1 to 6, characterized in that it comprises one or more NO₂

groups bonded to the hormone directly via the oxygen atom of the enolic form or by means of a benzyloxy radical.

5 8. A compound as claimed in any one of claims 1 to 7, characterized in that the NO_2 group(s) is (are) bonded directly to the hormone via the oxygen atom of the enolic form of the hormone.

10 9. A compound as claimed in any one of claims 1 to 7, characterized in that the NO_2 group(s) is (are) bonded to the hormone by means of a benzyloxy radical.


15 10. A compound as claimed in claim 9, characterized in that the benzyloxy radical is bonded to the hormone by means of a group that establishes a bridge.



11. A compound as claimed in claim 10, characterized in that the bridge is a $\text{C}=\text{O}$ or COO .

20 12. A compound as claimed in any one of claims 1 to 11, characterized in that the hormone capable of binding to hormone receptors is progesterone.

25 13. A compound as claimed in any one of claims 1 to 11, characterized in that the hormone capable of binding to hormone receptors is 17 α H-progesterone.

30 14. A compound as claimed in claim 7, characterized in that it corresponds to the formulae:





5 15. A compound as claimed in any one of claims 1 to 11, characterized in that the hormone capable of



binding to hormone receptors is estradiol.

16. A compound as claimed in claim 15, characterized in that it is substituted in the 17- and 3-position of 5 the estradiol with an NO₂ group bonded to the oxygen atom of the OH function of the estradiol.

17. A compound as claimed in claim 15, characterized in that it is substituted in the 3-position of the 10 estradiol with an NO₂ group bonded to the oxygen atom of the OH function of the estradiol.

18. A compound as claimed in claim 16 or 17, characterized in that it corresponds to the formulae

15




19. A compound as claimed in any one of claims 1 to 6, characterized in that the hormone capable of binding to 20 hormone receptors is spironolactone.

20. A compound as claimed in claim 19, characterized in that it comprises an NO₂ group bonded by means of a benzyloxy radical.

25

21. A compound as claimed in claim 20, characterized in that it corresponds to the formula



22. A compound as claimed in any one of claims 1 to 21, for its use as medicinal product.

5

23. A pharmaceutical composition characterized in that it comprises, in a pharmaceutically acceptable medium, a compound as claimed in any one of claims 1 to 21.

10 24. A medicinal product characterized in that it contains at least one compound as claimed in any one of claims 1 to 21, in the prevention of premature births.

15 25. The medicinal product as claimed in claim 24, for its therapeutic use in the prevention of premature births.

20 26. The medicinal product as claimed in claim 24, for its therapeutic use in the control of uterine mobility.

27. The medicinal product as claimed in claim 24, for its therapeutic use in increasing cervical dilatation during labor.

25 28. The medicinal product as claimed in claim 24, for its therapeutic use in the treatment of uterine contraction anomalies.

29. The medicinal product as claimed in claim 24, for 30 its therapeutic use in the treatment of dysmenorrhea.

30. The medicinal product as claimed in claim 24, for its therapeutic use in hormone replacement therapy in

menopausal women.

31. The medicinal product as claimed in claim 24, for
its therapeutic use in the induction of an endometrial
5 cycle in the context of assisted reproduction.

32. The medicinal product as claimed in claim 24, for
its therapeutic use in the prevention or treatment of
arterial hypertension.

10

33. The use of a compound characterized in that it is
capable of binding to hormone receptors and in that it
comprises a nitrogen monoxide-donor nitric ester group,
for preparing a medicinal product intended for the
15 prevention of premature births.